Breakthrough synapse-regenerating ALS pill moves to phase 2 human trials
A pioneering once-a-day pill that regenerates nerve cell connections damaged by ALS has been FDA-approved for ongoing clinical trials. The drug is now being given to those with ALS and could be a watershed moment in the treatment of the fatal disease.
newatlas.com